Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | IL6 | P05231 | 1/20 | 0.58 |
| ▸ | F3 | P13726 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MGAM | O43451 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | SI | P14410 | 3/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17691388 | 1.00 | MIF (0.64) | MIFHSD11B1TNFIL6F3 | |
| SCHEMBL3581740 | 1.00 | MIF (0.64) | MIFHSD11B1TNFIL6F3 | |
| SCHEMBL1524257 | 0.87 | ALDH1A1 (0.58) | MIFHSD11B1TNFIL6F3 | |
| SCHEMBL1524256 | 0.87 | ALDH1A1 (0.58) | MIFHSD11B1TNFIL6F3 | |
| SCHEMBL7132282 | 0.84 | IKBKB (0.65) | MIFHSD11B1GAAALDH1A1MAPT | |
| SCHEMBL17691431 | 0.84 | IKBKB (0.65) | MIFHSD11B1GAAALDH1A1MAPT | |
| SCHEMBL17691411 | 0.81 | IKBKB (0.64) | MIFHSD11B1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1524448 | 0.81 | MIF (0.63) | MIFHSD11B1TNFIL6CYP1A2 | |
| SCHEMBL1524449 | 0.81 | MIF (0.63) | MIFHSD11B1TNFIL6CYP1A2 | |
| SCHEMBL6208183 | 0.81 | MIF (0.51) | MIFHSD11B1TNFIL6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842705-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | EMORY UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| US-7371766-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | EMORY UNIVERSITY | 2005-03-31 | — | — | US | disclosed |
| WO-2005025623-A2 | EF-24-FACTOR VII CONJUGATES | EMORY UNIVERSITY (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2004-09-09 | — | — | US | disclosed |
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | disclosed |
| EP-1242379-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | Emory University (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040188-A9 | CURCUMIN ANALOGUES FOR TREATING CANCER | UNIV EMORY (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2002-02-14 | — | — | US | disclosed |
| WO-2001040188-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | EMORY UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | MIF 284/4885HSD11B1 3710/4885TNF 96/4885 |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | VEGFA, AGER, HDGF | MIF 1525/4885HSD11B1 4339/4885TNF 410/4885 |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | PGF, VEGFA, VHL | MIF 284/4885HSD11B1 3710/4885TNF 96/4885 |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | MIF 284/4885HSD11B1 3710/4885TNF 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.